MX2020008860A - Lisinas plyss2 modificadas y sus usos. - Google Patents

Lisinas plyss2 modificadas y sus usos.

Info

Publication number
MX2020008860A
MX2020008860A MX2020008860A MX2020008860A MX2020008860A MX 2020008860 A MX2020008860 A MX 2020008860A MX 2020008860 A MX2020008860 A MX 2020008860A MX 2020008860 A MX2020008860 A MX 2020008860A MX 2020008860 A MX2020008860 A MX 2020008860A
Authority
MX
Mexico
Prior art keywords
amino acid
methods
modified lysin
disclosed
modified
Prior art date
Application number
MX2020008860A
Other languages
English (en)
Inventor
Raymond Schuch
Michael Wittekind
Chiara Indiani
Original Assignee
Contrafect Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Contrafect Corp filed Critical Contrafect Corp
Publication of MX2020008860A publication Critical patent/MX2020008860A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462—Lysozyme (3.2.1.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24075—Lysostaphin (3.4.24.75)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En el presente documento se describen polipéptidos de lisina modificados que comprenden al menos una sustitución de aminoácidos en comparación con un polipéptido de lisina PlySs2 de tipo salvaje que tiene una secuencia de aminoácidos de la SEQ ID NO: 1, en el que la al menos una sustitución de aminoácidos está en el dominio CHAP y/o el dominio SH3b, y en el que el polipéptido de lisina modificado o fragmento del mismo inhibe el crecimiento, reduce la población, o mata al menos una especie de bacterias Grampositivas. También se describen en este documento composiciones que comprende los polipéptidos de lisina modificados, al igual que vectores que comprenden una molécula de ácido nucleico que codifica el polipéptido de lisina modificado. También se describen en este documento métodos para inhibir el crecimiento, reducir la población, o matar al menos una especie de bacterias Grampositivas, métodos para tratar una infección bacteriana, y métodos para aumentar la eficacia de un antibiótico o reducir el desarrollo de resistencia a los antibióticos.
MX2020008860A 2018-02-26 2019-02-26 Lisinas plyss2 modificadas y sus usos. MX2020008860A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862635515P 2018-02-26 2018-02-26
PCT/US2019/019638 WO2019165454A1 (en) 2018-02-26 2019-02-26 Modified plyss2 lysins and uses thereof

Publications (1)

Publication Number Publication Date
MX2020008860A true MX2020008860A (es) 2020-12-10

Family

ID=67687985

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008860A MX2020008860A (es) 2018-02-26 2019-02-26 Lisinas plyss2 modificadas y sus usos.

Country Status (12)

Country Link
US (1) US20210032294A1 (es)
EP (1) EP3758738A4 (es)
JP (1) JP2021513865A (es)
KR (1) KR20200124724A (es)
CN (1) CN112118861A (es)
AU (1) AU2019224160A1 (es)
BR (1) BR112020017219A2 (es)
CA (1) CA3092109A1 (es)
IL (1) IL276807A (es)
MX (1) MX2020008860A (es)
RU (1) RU2020128276A (es)
WO (1) WO2019165454A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210151188A (ko) * 2019-04-11 2021-12-13 콘트라펙트 코포레이션 뼈 및 관절 감염증의 치료 및 예방 방법
JP2023526386A (ja) * 2020-05-19 2023-06-21 コントラフェクト コーポレイション グラム陽性細菌に対して使用される修飾ＰｌｙＳｓ２溶解素及び抗生物質の組合せ
WO2023049747A1 (en) * 2021-09-22 2023-03-30 Elanco Us Inc. Streptococcus suis lytic enzyme compositions and methods of use thereof
WO2023081691A1 (en) * 2021-11-04 2023-05-11 Contrafect Corporation Method of treating and preventing bone and joint infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3252155A1 (en) * 2011-04-21 2017-12-06 The Rockefeller University Streptococcus bacteriophage lysins for detection and treatment of gram positive bacteria
SG194776A1 (en) * 2011-05-04 2013-12-30 Micreos Human Health Bv A polypeptide
KR20210118980A (ko) * 2012-05-09 2021-10-01 콘트라펙트 코포레이션 박테리오파지 리신을 이용한 생물막의 예방, 붕괴 및 치료
KR20230113404A (ko) * 2012-05-09 2023-07-28 콘트라펙트 코포레이션 그람 양성 박테리아에 대한 박테리오파지 리신과 항생제의병용물
CN104073478A (zh) * 2014-06-13 2014-10-01 上海交通大学 杀灭革兰氏阳性菌的酶抗生素及其制备、用途
WO2017197227A1 (en) * 2016-05-12 2017-11-16 Contrafect Corporation Broth microdilution method for evaluating and determining minimal inhibitory concentration of antibacterial polypeptides

Also Published As

Publication number Publication date
JP2021513865A (ja) 2021-06-03
CN112118861A (zh) 2020-12-22
BR112020017219A2 (pt) 2020-12-22
KR20200124724A (ko) 2020-11-03
WO2019165454A1 (en) 2019-08-29
EP3758738A4 (en) 2021-12-08
AU2019224160A1 (en) 2020-09-10
IL276807A (en) 2020-10-29
RU2020128276A (ru) 2022-03-29
US20210032294A1 (en) 2021-02-04
CA3092109A1 (en) 2019-08-29
EP3758738A1 (en) 2021-01-06

Similar Documents

Publication Publication Date Title
MX2020008860A (es) Lisinas plyss2 modificadas y sus usos.
Defer et al. Antimicrobial peptides in oyster hemolymph: the bacterial connection
MX2020010071A (es) Polipeptidos anti-microbianos, derivados de bacteriofago, y sus usos contra bacterias gram negativas.
AU2016231141B2 (en) Combination of bactericidal agent with a lysosomotropic alkalinising agent for the treatment of a bacterial infection
JP2021508235A5 (es)
MX2021015563A (es) Polipéptidos anti-microbianos, derivados de bacteriófago, y sus usos contra bacterias gramnegativas y acidorresistentes.
KR101655781B1 (ko) 항균 활성을 갖는 신규한 바실러스 테퀄엔시스 hd15 균주 및 이로부터 박테리오신을 생산하는 방법
KR101796279B1 (ko) 새로운 호스트 바인딩 도메인을 갖는 포도상구균 박테리오파지 SA11 유래의 엔도라이신 LysSA11 및 이를 포함하는 세균 사멸용 조성물
Perumal et al. Purification and characterization of a bacteriocin, BacBS2, produced by Bacillus velezensis BS2 isolated from Meongge Jeotgal
BR9205760A (pt) Proteínas antimicrobiais, proteína pura MJ-AMPI, proteínas puras, sequência de DNA recombinante, vetor, sistema biológico, plantas, composição antimicrobial, processo para combater fungos ou bactérias e processo de extração para produzir proteínas biocidamente ativas
WO2018155813A3 (ko) 엔테로코쿠스 패슘에 대하여 용균력을 가지는 신규한 항균단백질 efal-2
ES2382466T3 (es) Péptidos inductores de bacteriocinas
WO2020085698A3 (ko) 낙지 방어단백질로부터 유도된 항균 펩타이드 또는 이의 단편, 및 이를 포함하는 항균 조성물
WO2019094938A3 (en) Methods and compositions for the treatment of wounds
WO2018100408A1 (en) Modified peptides
MX2021011361A (es) Proteinas de fusion, bacterias recombinantes y fragmentos de exosporios para la salud de las plantas.
KR101985663B1 (ko) 꽃게 유래의 항균 펩타이드 및 그의 용도
Mohd-Yusoff et al. Trypsin inhibitor isolated from Streptomyces misionensis UMS1 has anti-bacterial activities and activates α-amylase
CN102120760B (zh) 一种来源于噬菌体的抗菌肽及其应用
EP4289949A1 (en) Bacteriophage lysine, chimera thereof and application thereof
JP6709395B2 (ja) 冷水病ワクチン及び冷水病の予防方法
US20100151097A1 (en) Optimization of colicin production
KR101384577B1 (ko) 황다랑어 유래의 새로운 항미생물성 펩타이드 및 이의 용도
Kim et al. Characterization of the Antimicrobial Substances Produced by Nibribacter radioresistens
MX2020007336A (es) Metodos y composiciones para modular la disfuncion de celulas endoteliales.